Compositions and methods to modulate
View Patent ↗The present invention discloses novel signaling pathways controlling the pathogenesis of the human respiratory bacterium, Haemophilus influenzae . The lipooligosaccharide-phosphorylycholine (LOS-PC) cell surface epitope of H. influenzae enhances pathogenesis but also increases bacterial susceptibility to innate and adaptive immunity and the administration of therapeutic compounds. Modulation of the LOS-PC epitope may be affected by an interaction between environmental conditions (i.e., for example, oxygen tension) and genetic regulation of precursor biosynthetic pathway activity. LOS-PC epitope display increases under microaerobic conditions and decreases under aerobic conditions. This is consisent with a bacteria's propensity to initiate pathogensis under low oxygen conditions. Pathogenesis may be prevented by disrupting the role of the putative H. influenzae homologue of CsrA, that downregulates galU expression. Disrupting CsrA repression of galU expression resulted in increased LOS-PC epitope display.
1. A method, comprising:
a) providing;
i) a bacteriophage capable of infecting an H. influenzae cell, wherein said bacteriophage comprises an oligonucleotide sequence complementary to a portion of the coding region of a wild type CsrA gene of said H. influenzae ; and
ii) one or more of said H. influenzae cells comprising said wild type CsrA gene, wherein said one or more H. influenzae cells have colonized a host animal; and
b) contacting said cells with said bacteriophage under conditions such that said oligonucleotide sequence hybridizes to said portion of the coding region of a wild type CsrA gene, wherein expression of said H. influenzae wild type CsrA gene is reduced.
2. The method of claim 1 , wherein said host animal is a human.
3. The method of claim 1 , wherein said oligonucleotide is completely complementary to said portion of said coding region.
4. The method of claim 1 , wherein said oligonucleotide is between 15 and 30 bases in length.
5. The method of claim 1 , wherein said bacteriophage is selected from the group consisting of HP1, HP2, S2A, B, C, N3, and φflu.